Jubilant Pharmova Q1 net profit up 82.43% at Rs160.56cr as Pharmaceutical EBITDA surges 170% yoy

Jubilant Pharmova reported 41.40% increase in total revenues for the Jun-21 quarter on consolidated basis at Rs1,634.65cr

Jul 24, 2021 01:07 IST India Infoline News Service

Jubilant Pharmova reported 41.40% increase in total revenues for the Jun-21 quarter on consolidated basis at Rs1,634.65cr. On a sequential basis, revenues were up 3.47% compared to Rs1,579.78cr revenues in Mar-21. The COVID 2.0 had limited impact on the revenues in the Jun-21 quarter.

The pharmaceuticals vertical grew by 40% yoy while the contract research and development (CDMO) also flattered the street with 50% yoy growth. The life sciences segment was hived off and shown as part of discontinued operations.

Net profit for the Jun-21 quarter was up 82.43% at Rs160.56cr on a yoy basis, but on a sequential basis, the PAT was lower by -24.94% due to COVID 2.0 impact. The EBITDA boost came from the pharma business which saw the EBITDA higher by nearly 170% yoy.

The EBITDA from CDMO also more than doubled yoy. The net margins at 9.82% for Jun-21 quarter is sharply better than 7.61% in the Jun-20 quarter but lower than 13.54% in the sequential Mar-21 quarter. However, previous numbers include discontinued operations.


Financial highlights for Jun-21 compared yoy and sequentially


Jubilant Pharmova
Rs in Crore Jun-21 Jun-20 YOY Mar-21 QOQ
Total Income (Rs cr) ₹ 1,634.65 ₹ 1,156.07 41.40% ₹ 1,579.78 3.47%
Net Profit (Rs cr) ₹ 160.56 ₹ 88.01 82.43% ₹ 213.90 -24.94%
Diluted EPS (Rs) ₹ 10.09 ₹ 5.53 ₹ 13.43
Net Margins 9.82% 7.61% 13.54%

Related Story

Open Free Demat Account (Rs699)